Clinical Trial

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-04; most recent amendment 2026-06-22.
Trial Details
NCT Number NCT07283640
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Amgen, Syndax Pharmaceuticals
Conditions Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
Enrollment 20 participants
Start Date 2026-11-18
Primary Completion 2029-08-31 (estimated)
Study Completion 2031-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12